FRAX597
中文名称 | FRAX597 |
---|---|
中文同义词 | I型P21激活激酶(PAK)抑制剂(FRAX597);6-(2-氯-4-(噻唑-5-基)苯基)-8-乙基-2-((4-(4-甲基哌嗪-1-基)苯基)氨基)吡啶并[2,3-D]嘧啶-7(8H)-酮;化合物FRAX597;FRAX 597,I类PAK抑制剂 |
英文名称 | 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one |
英文同义词 | 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one;FRAX597;Pyrido[2,3-d]pyriMidin-7(8H)-one, 6-[2-chloro-4-(5-thiazolyl)phenyl]-8-ethyl-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-;6-(2-chloro-4-(thiazol-5-yl)phenyl)-8-ethyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one;6-[2-Chloro-4-(5-thiazolyl)phenyl]-8-ethyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one;FRAX597, >=98%;6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one USP/EP/BP;6-[2-chloro-4-(1,3-thiazol-5-yl)phenyl]-8-ethyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-one |
CAS号 | 1286739-19-2 |
分子式 | C29H28ClN7OS |
分子量 | 558.1 |
EINECS号 | |
相关类别 | 小分子抑制剂,天然产物;抑制剂;细胞生物学试剂;Inhibitors;API |
Mol文件 | 1286739-19-2.mol |
结构式 |
FRAX597 性质
熔点 | >220°C (dec.) |
---|---|
储存条件 | Refrigerator |
溶解度 | 二甲基亚砜(微溶) |
形态 | 固体 |
颜色 | 粘黄色 |
FRAX597是一种有效的,ATP竞争性的第一类PAKs抑制剂,对PAK1,PAK2,和 PAK3 的 IC50 分别为 8 nM,13 nM,和 19 nM。FRAX597 (100 n M) displays a significant inhibitory capacity toward YES1 (87%), RET (82%), CSF1R (91%), TEK (87%), PAK1 (82%), and PAK2 (93%), while displays minimal inhibitory activity towards the group II PAKs: PAK4 (0%), PAK6 (23%), and PAK7 (8%). FRAX597 treatment dramatically impairs the proliferation of Nf2-null SC4 Schwann cells (SC4 cells). FRAX597 displays an IC50 value of 48 nM against wild type PAK1, while IC 50 values against the V342F and V342Y PAK1 mutants are higher than 3μM and 2 μM, respectively. FRAX597 inhibits the proliferation and motility of both benign (Ben-Men1, 3μM) and malignant (KT21-MG1, 0.4 μM) meningiomas cells after treating of 72 h.In NOD/SCID mice which bearing Nf2-/-SC4 Schwann cells, FRAX597 (100 mg/kg/day, p.o.) causes more significant tumor growth inhibition cpmpared with control mice. In SCID mice with orthotopic meningioma, FRAX597 (90 mg/kg/day, p.o.) significantly suppresses tumor growth. In KrasG12D mice, treatment with FRAX597 (90 mg/kg/day, p.o.) causes tumor regression and loss of Erk and Akt activity.
PAK1 8 nM (IC 50 ) |
PAK2 13 nM (IC 50 ) |
PAK3 19 nM (IC 50 ) |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-15542A | FRAX597 FRAX597 | 1286739-19-2 | 2mg | 400元 |
2024/08/19 | HY-15542A | FRAX597 FRAX597 | 1286739-19-2 | 5mg | 850元 |